Life Sciences Tools and Services

Bionano Genomics

Maxim Group Analyst Gives Buy Rating to BioNano Genomics

Bionano Genomics released FY2025 9 Months Earnings on November 13 After-Market EST, with actual revenue of USD 20.56 M and EPS of USD -4.737

Bionano Genomics released FY2025 Q3 earnings on November 13 After-Market EST, actual revenue USD 7.367 M (forecast USD 6.906 M), actual EPS USD -1.5929 (forecast USD -2.075)

Bionano Genomics to Release FY2025 Q3 Earnings on November 13 After-Market EST, Forecast Revenue USD 6.906 M, EPS USD -2.075

Bionano Genomics released FY2025 Q2 earnings on August 14 After-Market EST, actual revenue USD 6.733 M (forecast USD 6.564 M), actual EPS USD -1.9927 (forecast USD -2.6666)

Bionano Genomics released FY2025 Semi-Annual Earnings on August 14 After-Market EST, with actual revenue of USD 13.19 M and EPS of USD -3.2436

Bionano Genomics to release FY2025 Q2 earnings on August 14 After-Market EST, forecast revenue USD 6.898 M, EPS USD -2.6466

Bionano Genomics Participates in ESHG to Showcase OGM Technology

Bionano Genomics Holds 2025 Annual Shareholders' Meeting

Maxim Group Upgrades Bionano Genomics to Buy

Bionano Genomics Rated as Outperform with a Target Price of $7

Bionano Genomics released FY2025 Q1 earnings on May 14 After-Market EST, actual revenue USD 6.457 M (forecast USD 6.25 M), actual EPS USD -1.1514 (forecast USD -3.0233)

Bionano Genomics Reports Q1 Revenue of $6.5 Million

Bionano Genomics Inc to Report a Quarterly Loss of $3.02 per Share in Q1 2025

Bionano Genomics to release FY2025 Q1 earnings on May 14 After-Market EST, forecast revenue USD 6.25 M, EPS USD -3.0233

Bionano Genomics Inc Expected to Report Earnings Loss of $3.02 per Share

Bionano Genomics released FY2024 Q4 earnings on March 31 After-Market (EST), actual revenue 8.163 M USD (forecast 6.2 M USD), actual EPS -12.2221 USD (forecast -5.9999 USD)

Bionano Genomics released FY2024 annual earnings on March 31 After-Market (EST), actual revenue 30.78 M USD (forecast 28.8 M USD), actual EPS -88.1329 USD (forecast -80.0998 USD)

Bionano Genomics Plans to Release Quarterly Earnings Report on March 31, 2025, Analysts Predict EPS of -8.40

Bionano Genomics to Release FY2024 Q4 Earnings on March 31 After-Market EST, Forecast Revenue 6.2 M USD, EPS -5.9999 USD

Sobr Safe

Omeros

Northann

AMC Robotics

Euda Health

Dynavax Tech

Multi Ways

Indaptus Therapeutics

Sidus Space

Kandal M Venture

Niagen Bioscience

ChromaDex

安捷倫科技

沃特世

西氏醫藥服務

藥明生物(ADR)

Medpace控股

Repligen

Stevanato Group SpA

Cryoport

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap